


# RECEIVED

#7-1

JUL 16 2002

Form <b>PTO #449</b>  US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO. <b>TECH CENTER 1600/2900</b> P-IM 5158	SERIAL NO. 10/056,420
	APPLICANT: Ronald B. Moss	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: January 24, 2002	GROUP: <del>1633</del> <b>1648</b>

## U.S. PATENT DOCUMENTS


EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
<i>J</i>	6,328,976	12/11/01	Ronald B. Luftig	424	208.1	4/3/1998
<i>J</i>	5,661,023	8/26/97	Hrinda et al.	435	239	3/11/1996
<i>J</i>	5,256,767	10/26/93	Salk et al.	530	350	11/10/1992

## FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)
<i>J</i>	WO 00/45844	8/10/00	PCT			
<i>J</i>	WO 00/67787	11/16/00	PCT			
<i>J</i>	WO 98/55495	12/10/98	PCT			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

<i>J</i>	Allende and Lane, "Cytokine-based therapies for HIV infection," <u>AIDS</u> 15:S183-191 (2001).
<i>J</i>	Altfeld and Walker, "Less is more? STI in acute and chronic HIV-1 infection," <u>Nature Medicine</u> 7:881-884 (2001)
<i>J</i>	Choi et al., "HIV type 1 isolate Z321, the strain used to make a therapeutic HIV type 1 immunogen, is intersubtype recombinant," <u>AIDS Res. Human Retroviruses</u> 13:357-361 (1997)

EXAMINER 	DATE CONSIDERED <b>12/12/03</b>
---	------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


RECEIVED

#7-2


JUL 16 2002

TECH CENTER 1600/2900

Page 2 of 4

Form <del>PTO</del> 1449  US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-IM 5158	SERIAL NO. 10/056,420
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT: Ronald B. Moss	
	FILING DATE: January 24, 2002	GROUP: 1633 1648

2	Churdboonchart et al., "A double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1 infected Thai subjects with CD4-cell counts of >300," <u>Clin. Diag. Lab. Immunol.</u> 7:728-733 (2000)
	Dybul et al., "Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: Effects on virologic, immunologic, and toxicity parameters," <u>PNAS</u> 98:15161-15166 (2001)
	Eron and Vernazza, "Alternative strategies for anti-HIV treatment," <u>AIDS</u> 15:S161-S169 (2001)
	Goh et al., "The Quest Trial, a paradigm of HIV collaborative research," <u>Nature Medicine</u> 6:1194 (2000)
	Gotch et al., "Therapeutic vaccines in HIV.1 infection," <u>Immunological Reviews</u> 170:173-182 (1999).
	John et al., "Control of HIV replication by cytotoxic T-lymphocyte response," <u>J. HIV Therapy</u> 4(4):90-96 (1999).
	Levine et al., "Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 immunogen: long-term follow up," <u>J. Acquired Immune Defic. Synd. Human Retrovir.</u> 11:351-364 (1996)
	Limsuwan et al., "Safety and immunogenicity of REMUNE in HIV-infected Thai subjects," <u>Vaccine</u> 16:142-149 (1998)
	Lori and Lisziewicz "Structured Treatment Interruptions for the Management of HIV infection," <u>JAMA</u> 286:2981-2987 (2001)
▼	Moss et al., "Delayed viral rebound in subjects who have discontinued antirival drug therapy after receiving an HIV-1 immunogen (REMUNE) is associated with in vitro cell-mediated immune responses to p24 antigen," <u>Proceedings of the XIII International AIDS Conference</u> Abstract # TuPeA3047, July 9-14 (2000)

EXAMINER 	DATE CONSIDERED 12/12/03
---	-----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


# RECEIVED




#7-3


JUL 16 2002

TECH CENTER 1600/2900

Page 3 of 4

Form <del>PTO</del> 1449 	US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-IM 5158	SERIAL NO. 10/056,420
	APPLICANT: Ronald B. Moss		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: January 24, 2002	GROUP: 1633 1648

	Moss et al., "The strategy of immunologic control of HIV-1 with structured treatment interruptions (STIs)," <u>Current Drug Targets-Infectious Disorders</u> 1:11-17 (2001).
	Moss, "Structured treatment interruptions after therapeutic HIV vaccination in primary and chronic HIV-1 infection," <u>J. of Human Virology</u> 4(3):2001-2005. International meeting of the Institute of Human Virology (September 9-13, 2001) Abstract only.
	Ortiz et al., "Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects," <u>PNAS</u> 98:13288-13293 (2001)
	Papasavvas et al., "Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption," <u>J. Infectious Diseases</u> 182:766-775 (2000).
	Peters, "The basis for HIV immunotherapeutic vaccines," <u>Vaccine</u> 20:688-705 (2002).
	Phillips et al., "HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load," <u>JAMA</u> 286:2560-2567 (2001).
	Richieri et al., "Characterization of highly purified, inactivated HIV-1 particles isolated by anion exchange chromatography," <u>Vaccine</u> 16:119-129 (1998)
	Scondras, "Treatment interruption research: the trial most needed now," <u>AIDS Treatment News</u> . United States, June 4, 1999. Outlined research proposal.
	Sutter and Haas, "Novel vaccine delivery systems: solutions to HIV vaccine dilemmas?," <u>AIDS</u> 15:S139-S145 (2001).

EXAMINER 	DATE CONSIDERED 12/12/03
---	-----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

